Streetbeat News

Regulatory

CRMD

CorMedix Inc. (NASDAQ:CRMD) has signed a 5-year supply contract with ARC Dialysis, LLC for DefenCath®, a product recently approved by the FDA for preventing infections in hemodialysis patients. This partnership aligns with CorMedix's strategy to establish long-term relationships with innovative dialysis providers. DefenCath®'s commercialization is set to begin on April 15th, following its approval under the LPAD on November 15, 2023. ARC Dialysis, known for its commitment to patient care and innovation, operates in approximately 100 inpatient and 18 outpatient facilities in Florida.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:41 pm

BTCUSD

XRPUSD

Ripple CEO Brad Garlinghouse predicts the cryptocurrency market cap could reach $5 trillion by 2024, driven by the launch of U.S. spot Bitcoin ETFs and the upcoming Bitcoin halving event. These developments, along with increased institutional investment, are expected to significantly impact the market dynamics. The first U.S. spot Bitcoin ETFs were approved on Jan. 10, and the Bitcoin halving event is set to occur later this month.

Portfolio Pulse from Murtuza Merchant

April 08, 2024 | 12:40 pm

JAGX

Jaguar Health, Inc. has been granted an extension until August 13, 2024, by Nasdaq to meet the $1.00 bid price requirement for continued listing. The company is also awaiting top line results from its Phase 3 OnTarget trial of crofelemer for the preventative treatment of cancer therapy-related diarrhea.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:40 pm

AUUD

Auddia Inc.'s shares surged following the announcement that the USPTO awarded the company U.S. Patent 11,935,520 for its core AI technology used in the faidr app, which offers ad-free AM/FM radio stations to paid subscribers.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:36 pm

CHRS

Coherus BioSciences, Inc. (NASDAQ:CHRS) presented preclinical data for CHS-1000, a novel anti-ILT4 antibody, at the 2024 AACR Annual Meeting. CHS-1000 shows high affinity for ILT4, reverses its immunosuppressive functions, and activates immune cells, suggesting potential to enhance antitumor responses with immunotherapy. CHS-1000 is the first immuno-oncology product developed by Coherus, with an IND submission planned for Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:34 pm

VSTO

Czechoslovak Group (CSG) has reaffirmed its $1.91 billion all-cash acquisition of Vista Outdoor (VSTO), with financing fully committed by JP Morgan Chase. CSG, a significant NATO supplier with top security clearance, operates ammunition facilities in Arkansas and Missouri, acquired in 2022 with CFIUS approval. The transaction has received FTC antitrust clearance.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:32 pm

SUPN

Supernus Pharmaceuticals' stock is trading lower following the FDA's issuance of a Complete Response Letter regarding the company's New Drug Application for SPN-830.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:20 pm

INMB

INmune Bio Inc. (NASDAQ:INMB) presented data on INB03, a novel immunotherapy for high-risk breast cancer, at AACR 2024. INB03 targets soluble TNF to modulate immune checkpoints, enhancing therapeutic outcomes in HER2+ and triple-negative breast cancer (TNBC). Studies showed INB03, in combination with anti-HER2 and anti-PD1 therapies, reduced tumor growth and metastasis by altering immune cell behavior and decreasing immune checkpoint proteins. The company seeks partners to advance clinical development and expand its patent portfolio for INB03 in oncology.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:16 pm

FCEL

XOM

FuelCell Energy, Inc. (FCEL) and ExxonMobil Technology and Engineering Company (EMTEC) have updated and extended their joint development agreement to accelerate access to carbonate fuel cell technology for carbon capture. This technology, which captures CO2 emissions while generating electricity and hydrogen, could lower the cost and barriers to carbon capture adoption. A pilot project is set to start in early 2026 at Esso Nederland BV's Rotterdam Manufacturing Complex. The agreement allows FuelCell Energy to market its carbon capture technology, enhanced by joint innovations, aiming to accelerate commercial delivery.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:07 pm

AAPL

NVDA

SMH

SOXX

TSM

Taiwan Semiconductor Manufacturing Co (TSMC) is significantly expanding its U.S. investment to over $65 billion, supported by a $6.6 billion federal grant, to produce advanced 2-nanometer chips. This includes building a third chip manufacturing facility in Phoenix, Arizona, by 2030, marking the largest foreign direct investment in U.S. history for a greenfield project. TSMC also aims for 60% local procurement for its first chip manufacturing facility in Japan by 2030. Despite a severe earthquake in Taiwan, TSMC maintains its annual revenue growth forecast. TSMC stock has gained 59% in the last 12 months, and investors can also gain exposure through VanEck Semiconductor ETF (SMH) and iShares Semiconductor ETF (SOXX).

Portfolio Pulse from Anusuya Lahiri

April 08, 2024 | 12:06 pm